Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Autoimmune Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 1813971

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1813971

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-Counter), By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Rheumatoid Arthritis Therapeutics Market Summary

The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.

The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company's interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.

In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sandoz's citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.

In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA's underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.

Global Rheumatoid Arthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

  • Molecule Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
    • TNF-a antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • Anti-IL6 biologics
    • Biosimilars
    • CD20 antigen
    • TNF-a antagonists
  • Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Prescription
  • Over-the-Counter (OTC)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-2-68038-313-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule
    • 1.2.2. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market: Molecule Business Analysis

  • 4.1. Molecule Market Share, 2024 & 2033
  • 4.2. Molecule Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2021 to 2033 (USD Million)
  • 4.4. Pharmaceuticals
    • 4.4.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.4.2. NSAIDs
      • 4.4.2.1. NSAIDs Market, 2021 - 2033 (USD Million)
    • 4.4.3. Analgesics
      • 4.4.3.1. Analgesics Market, 2021 - 2033 (USD Million)
    • 4.4.4. DMARDs
      • 4.4.4.1. DMARDs Market, 2021 - 2033 (USD Million)
    • 4.4.5. Glucocorticoids
      • 4.4.5.1. Glucocorticoids Market, 2021 - 2033 (USD Million)
  • 4.5. Biopharmaceuticals
    • 4.5.1. Biopharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market, 2021 - 2033 (USD Million)
      • 4.5.2.2. TNF-a antagonists
        • 4.5.2.2.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)
      • 4.5.2.3. T-cell inhibitors
        • 4.5.2.3.1. T-cell inhibitors Market, 2021 - 2033 (USD Million)
      • 4.5.2.4. CD20 antigen
        • 4.5.2.4.1. CD20 antigen Market, 2021 - 2033 (USD Million)
      • 4.5.2.5. JAK inhibitors
        • 4.5.2.5.1. JAK inhibitors Market, 2021 - 2033 (USD Million)
      • 4.5.2.6. Anti-IL6 biologics
        • 4.5.2.6.1. Anti-IL6 biologics Market, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilars
      • 4.5.3.1. Biosimilars Market, 2021 - 2033 (USD Million)
      • 4.5.3.2. CD20 antigen
        • 4.5.3.2.1. CD20 antigen Market, 2021 - 2033 (USD Million)
      • 4.5.3.3. TNF-a antagonists
        • 4.5.3.3.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market: Sales Channel Business Analysis

  • 5.1. Sales Channel Market Share, 2024 & 2033
  • 5.2. Sales Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription Market, 2021 - 2033 (USD Million)
  • 5.5. Over-the-Counter (OTC)
    • 5.5.1. Over-the-Counter (OTC) Market, 2021 - 2033 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Molecule Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Boehringer Ingelheim International GmbH
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Molecule Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Novartis AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Molecule Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Regeneron Pharmaceuticals Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Molecule Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Molecule Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bristol-Myers Squibb Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Molecule Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. F. Hoffmann-La Roche Ltd.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Molecule Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. UCB S.A.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Molecule Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Johnson & Johnson Services, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Molecule Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Amgen, Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Molecule Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Lilly (Eli Lilly and Company)
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Molecule Benchmarking
      • 7.5.11.4. Strategic Initiatives
Show more
Product Code: GVR-2-68038-313-3

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 4 Global rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 5 North America rheumatoid arthritis therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 6 North America rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 7 North America rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 8 U.S. rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 9 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 10 Canada rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 11 Canada rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 12 Mexico rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 13 Mexico rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 14 Europe rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 15 Europe rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 16 Europe rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 17 UK rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 18 UK rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 19 Germany rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 20 Germany rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 21 France rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 22 France rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 23 Italy rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 24 Italy rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 25 Spain rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 26 Spain rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 27 Norway rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 28 Norway rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 29 Sweden rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 30 Sweden rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 31 Denmark rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 32 Denmark rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 36 Japan rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 37 Japan rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 38 China rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 39 China rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 40 India rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 41 India rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 42 Australia rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 43 Australia rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 44 South Korea rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 45 South Korea rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 46 Thailand rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 47 Thailand rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 48 Latin America rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Latin America rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 50 Latin America rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 51 Brazil rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 52 Brazil rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 53 Argentina rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 54 Argentina rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 55 Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 58 South Africa rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 59 South Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 62 UAE rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 63 UAE rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 64 Kuwait rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 65 Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Rheumatoid arthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and molecule outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Rheumatoid arthritis therapeutics market dynamics
  • Fig. 12 Rheumatoid arthritis therapeutics market: Porter's five forces analysis
  • Fig. 13 Rheumatoid arthritis therapeutics market: PESTLE analysis
  • Fig. 14 Molecule market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 15 Biopharmaceuticals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 TNF-a antagonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 T-cell inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 CD20 antigen market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 JAK inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Anti-IL6 biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Biosimilars market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 CD20 antigen market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 TNF-a antagonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Pharmaceuticals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 NSAIDs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Analgesics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 DMARDs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Glucocorticoids market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
  • Fig. 31 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
  • Fig. 32 Prescription market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Over-the-Counter (OTC) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Rheumatoid arthritis therapeutics market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 US country dynamics
  • Fig. 38 US rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Latin America rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 MEA rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!